Under the strategic agreement, the companies expect to launch two products in the first half of 2008. IntelGenx will complete the development of the products, using its patented proprietary delivery technologies, and will be entitled to royalties on Azur’s net US revenues from the products. Azur will be responsible for commercialization and marketing activities in the US.
Horst Zerbe, president and CEO of IntelGenx, said: “This agreement marks an important milestone for IntelGenx, as it represents the commercialization of the first product using our drug delivery technologies.”